Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR statusA subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received either 1 or ≥2 prior lines of therapyData from the TOTEM trial reporting survival outcomes for patients undergoing intensive vs minimalist follow-up in following treatment for endometrial cancerAn exploratory analysis from the phase III ARIEL3 trial evaluating characteristics of patients with ovarian cancer with exceptional benefit from rucaparibA post hoc analysis from the phase III NORA trial assessing efficacy of starting PARP inhibitor maintenance following either ≤4 vs 4 cycles of platinum-based chemotherapyHighly anticipated results from the phase III EMPOWER-CERVICAL 1 trial of cemiplimab vs investigator’s choice chemotherapy in women with cervical cancerPresenters:Domenica Lorusso, MD, PhDAssociate ProfessorGynecologic Oncology DepartmentClinical Research UnitFondazione Policlinico Gemelli IRCCSRome, ItalyAlexandra Leary, MD, PhDMedical Oncologist and Team Leader  Gynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, FranceContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/3dAttwi

There are no comments yet.

Please log in to write the first comment.